MS drugs boost Biogen Q2 results
BiopharmaReporter.com - London,UK
... sales of Tysabri - a treatment for multiple sclerosis (MS) that Biogen co-markets with Elan - totalled $72m in the period, of which $48m goes to Biogen. ...
See all stories on this topic

Elan falls on jitters over MS, Alzheimer's drugs
Reuters - USA
"The move lower is on the back of slightly weaker sales of Tysabri and the Neurochem announcement," said one Dublin-based trader. ...
See all stories on this topic

Competitor of Teva's Copaxone could reach $2b sales in 2010
Globes - Rishon Le-Zion,Israel
In February 2005, Tysabri was taken of the shelves when three patients died of a rare nervous disorder, progressive multifocal leukoencephalopathy (PML), ...
See all stories on this topic